Kornimate/medical-research-clean huggingface dataset:
effect of intravenous vitamin c on sofa score among septic patients

Conditions: Sepsis

Summary: this study aimed to explore the effect of intravenous (iv) vitamin c on sequential organ failure assessment (sofa) score among septic patients in intensive care unit (icu).

"this study was approved by the ethics and research committee of universitas indonesia. this study was a randomized clinical trial held from april to july 2019 in cipto mangunkusumo hospital. 33 patients that met the inclusion criteria were included in the study. subjects were divided into two groups: group a (intervention group, n = 18) received parenteral infusions of 1,5 g/6 hours of vitamin c and 200 mg thiamine, while group b (control group, n = 15) received 200 mg thiamine only. baseline demographic data was recorded on the first day. sofa score was recorded at baseline, 24 hours, 48 hours, and 72 hours after treatment. data were analyzed using spss (statistical package for social sciences) software."

Eligibility criteria:
inclusion criteria: * patients with sepsis diagnosis based on sepsis-3 criteria in the icu in between 6 hours to 24 hours post resuscitation after sepsis diagnosis exclusion criteria: * patients with chronic kidney problems on haemodialysis, * patients with kidney stones or kidney problem within the last 3 months

Keywords: sepsis intravenous vitamin c sofa score
comparison of the efficacy of high intensity laser therapy and low level laser therapy in the carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome; Electromyography; Low-Level Laser Therapy; Ultrasound Imaging

Summary: carpal tunnel syndrome is the most common entrapment neuropathy and is frequently encountered in clinical practice. although there is no standard protocol for its treatment, conservative treatment methods are preferred. in our study, we aimed to clinically compare the efficacy of high and low intensity laser treatments in patients with carpal tunnel syndrome. by using methods such as electromyography and ultrasound, we aimed to provide a more objective evaluation

our study was designed as a prospective, randomised, controlled, single-centre trial. a total of 63 patients aged 18-65 years with electrophysiologically diagnosed mild to moderate carpal tunnel syndrome and 114 hands were included in the study. patients were divided into 3 groups. patients in all three groups wore a neutral wrist splint of appropriate size. the second group included patients who additionally received low level laser therapy (lllt), and the third group included patients who additionally received high intensity laser therapy (hilt). all groups underwent clinical, electrophysiological, and ultrasonographic examinations at the beginning of the treatment, at 1st month, and at 3rd month after the treatment.

Eligibility criteria:
inclusion criteria: 1. age between 18 to 65 years 2. mild cts (sensory conduction velocity at the second finger wrist \ 3.60 msec) according to the electrophysiological data were included in the study. exclusion criteria: 1. patients with local (osteophytes, ganglion cysts, lipomas, muscle and tendon abnormalities, etc.) and systemic (diabetes mellitus, acromegaly, hypothyroidism, pregnancy, etc.) diseases causing symptoms were included in the study.) causing cts, 2. patients who underwent surgical treatment for cts 3. patients who received injections for cts in the last 6 months 4. patients diagnosed with severe cts on emg (sap not obtained in sensory conduction studies and/or cmap \< 5 mv in motor conduction studies)
a study to compare the efficacy and safety of bms-986489 (bms-986012+ nivolumab fixed dose combination) in combination with carboplatin plus etoposide to that of atezolizumab with carboplatin plus etoposide as first-line therapy in participants with extensive-stage small cell lung cancer (tigos).

Conditions: Extensive-Stage Small Cell Lung Cancer

Summary: the purpose of the study is to compare the efficacy and safety of bms-986489 (anti-fucosyl-gm1+ nivolumab fixed dose combination) in combination with carboplatin plus etoposide to that of atezolizumab with carboplatin plus etoposide as first-line therapy in participants with extensive-stage small cell lung cancer.


Eligibility criteria:
inclusion criteria: * participants must have diagnosis of extensive-stage small cell lung cancer (es-sclc). * participants must be healthy enough to do their normal activities with little or no help based on the ecog performance scale. * participants must have at least one tumor that can be measured using special imaging techniques like a ct scan or mri at a site other than the brain and nervous system exclusion criteria: * participants have already received certain types of treatment for extensive stage small cell lung cancer * participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy * other protocol-defined inclusion/exclusion criteria apply.

Keywords: bms-986489 bms-986012 extensive-stage small cell lung cancer etoposide carboplatin nivolumab tigos fucgm1 sclc es-sclc
confocal laser endomicroscopy in patients with eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: confocal laser endomicroscopy enables in vivo microscopic imaging within the mucosa layer of the gut at a subcellular resolution. various studies have addressed the potential of endomicroscopy for the in vivo diagnosis of esophageal squamous cell carcinoma, barrett´s esophagus and esophageal adenocarcinoma. currently, there is only one case report from our group who noted the utility of endomicroscopy for the in vivo diagnosis of eosinophilic esophagitis. the purpose of this study is to determine whether endomicroscopy is effective for the in vivo diagnosis of eosinophilic esophagitis.


Eligibility criteria:
inclusion criteria: * written informed consent * age 18-85 years * ability of subjects to understand character and individual consequences of clinical trial * subjects undergoing egd exclusion criteria: * inability to provide written informed consent * severe coagulopathy (prothrombin time \ 50 s) * impaired renal function (creatinine \> 1.2 mg/dl) * pregnancy or breast feeding * active gastrointestinal bleeding * known allergy to fluorescein, acriflavin or cresyl violet * residing in institutions (e.g. prison)
first responder resiliency program during covid-19

Conditions: Resilience; Stress; Sleep

Summary: evaluating a wellness program developed to provide effective sustainable solutions for medical professionals providing care to covid-19 pandemic patients.

providing mindfulness training at specific time points during study participation with an emphasis on integrating physical and mental health management. the phase-based program delivers individualized, data-driven and quantifiable solutions that directly address pain points impacting healthcare professionals and organizations.

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older at the time of consent 2. frontline healthcare professional 3. have access to an apple or android device 4. not pregnant by subject self-report at time of consent 5. have the ability to provide informed consent 6. have no contraindicating comorbid health condition as determined by the clinical investigators exclusion criteria: 1. currently (within the past 3 weeks) been practicing mindfulness training on a weekly/regular basis 2. currently (within the past 3 weeks) been undergoing an additional program (e.g. cam) to improve quality of life or sleep 3. currently (within 3 weeks) been enrolled in another clinical or research program (e.g. cam) which intervenes on the patients' qol, stress or sleep 4. an unstable medical or mental health condition as determined by the physician investigator
ubt as a diagnostic tool for hp prevalance

Conditions: Dyspepsia

Summary: the prevalence of h. pylori infection in pakistan is unknown and investigators want to assess it in dyspeptic patients utilizing ubt. at the same time investigators want to validate ubt sensitivity and specificity in pakistani patients

the non-invasive methods for the diagnosis of hp are the urea breath test (ubt) and serological tests. the serological tests includes elisa test in serum for hp antibody and in stool for hp antigen. serum elisa hp antibody is not sensitive for showing active infection and the titres do not decrease even after successful eradication. serology test cannot be used for those who have previously been treated for hp, as the decline in titre of hp antibodies is too slow to be of practical use. the stool hp antigen detection test is more sensitive and specific as it detects bacterial antigens which will only be positive in the presence of hp. however, it is cumbersome to collect stool and laboratory services are required. the c14 urea breath test (ubt) is an office based test with sensitivity and specificity comparable to that of the stool antigen test. the diagnostic validity of these tests depends on the prevalence of h pylori infection. a higher prevalence would be associated with higher sensitivity and lower specificity. the safety profile of the urea breath test is very favourable, and no major side effects are associated with it. the aims of this study are to estimate h pylori prevalence in pakistan among the adult dyspeptic population and to validate the sensitivity and specificity ubt in our population

Eligibility criteria:
inclusion criteria: * male and female subjects with dyspeptic symptoms (b1 criteria of fd) * subject who has not been treated for h pylori eradication in the past * age above 18 years * no alarm symptoms of : * gastrointestinal bleeding * anemia * early satiety * unexplained weight loss * progressive dysphagia * odynophagia * recurrent vomiting * family history of gi malignancy * previous gi malignancy exclusion criteria: * pregnant females * use of nsaids * use of anti- secretory agent (h2 blockers) and proton pump inhibitors in previous 4 weeks * use of anti- microbial agents (clarithromycin, metronidazole, amoxacillin, quinalones) or bismuth in last 4 weeks * .gastric and/or duodenal erosions or ulcers, polyps or malignancy if noted on endoscopy will be excluded. * patients with predominant symptoms or gastro esophageal reflux disease (gerd) or endoscopic evidence of esophagitis. * patients with abnormal upper abdominal ultrasound.

Keywords: helicobacter pylori ubt sensitivity specificity prevalence
inhibition of lipid peroxidation during cardiac surgery

Conditions: Cardiopulmonary Bypass Induced Lipid Peroxidation

Summary: acute kidney injury is a major complication of cardiac surgery requiring cardiopulmonary bypass (cpb). hemolysis and rhabdomyolysis frequently occur during cpb. hemolysis leads to an increase in free hemoglobin, whereas rhabdomyolysis leads to an increase in myoglobin. free plasma hemoglobin and myoglobin have been shown to be independent predictors of the acute kidney injury that results from cpb. when these hemeproteins are released into the plasma, they undergo redox cycling, generating radical species that initiate lipid peroxidation and a cascade of oxidative damage to cellular membranes, notably in the kidney. f2-isoprostanes and isofurans are sensitive and specific markers of oxidative stress in vivo, and are increased after cpb, particularly in those patients with acute kidney injury. acetaminophen inhibits the lipid peroxidation catalyzed by myoglobin and hemoglobin. moreover, in an animal model of rhabdomyolysis-induced kidney injury, acetaminophen significantly attenuated the decrease in creatinine clearance compared to control. the current proposal tests the central hypothesis that acetaminophen will attenuate the lipid peroxidation associated with the hemolysis and rhabdomyolysis that occur in patients undergoing cpb. demonstration that acetaminophen inhibits the lipid peroxidation resulting from cpb would provide a rationale for a prospective randomized trial to test the hypothesis that acetaminophen will reduce the acute kidney injury that results from cpb.


Eligibility criteria:
inclusion criteria: 1. subjects, 18 to 80 years of age, scheduled for elective cardiac surgery requiring cpb 2. for female subjects, the following conditions must be met: postmenopausal for at least 1 year, or status-post surgical sterilization, or if of childbearing potential, utilizing adequate birth control and a negative urine beta-hcg prior to drug treatment exclusion criteria: 1. allergic reaction to apap (acetaminophen) 2. evidence of severe hepatic impairment (history of liver cirrhosis or total bilirubin \>2.0mg/dl) 3. impaired renal function (serum creatinine \>2.0 mg/dl) 4. emergency surgery 5. pregnancy 6. breast-feeding 7. any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult 8. history of alcohol or drug abuse 9. treatment with any investigational drug in the 1 month preceding the study 10. mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study 11. inability to comply with the protocol, e.g. uncooperative attitude and unlikelihood of completing the study 12. history or evidence of active asthma

Keywords: oxidative stress cardiopulmonary bypass acetaminophen hemolysis
chlorhexidine antiseptic irrigation of the bowel segment during radical cystectomy and urinary diversion

Conditions: Bladder Cancer; Urinary Tract Infection

Summary: this is a single arm, interventional pilot study of using chlorhexidine irrigation intra-operatively and post-operatively among patients undergoing radical cystectomy with urinary diversion. the intervention comprises of using irrigation of ileal conduit or ileal neobladder intra-operatively and then for irrigation of either post-surgery with irrisept ®. the sterilization of urine will be assessed at 10 days after cystectomy. incidence of symptomatic urinary tract infections within the 30-day post-operative period will be estimated.

th research team proposes to increase the rate of sterilization of urine from patients with urinary diversion and reduce the incidence of uti up to 30 ± 7 days post radical cystectomy and urinary diversion using 50 ± 25ml of irrisept ® irrigation solution lavage of the bowel segment during surgery for a contact time of 2 minutes. for patients who obtain an ileal conduits irrigation using 50 ± 25ml of irrisept ® will be performed daily for 10 days +/- 3 days and for those patients obtaining ileal neobladders irrigation using 50 ± 25ml of irrisept ® will continue for 21 days +/- 7 days. the irrigation will continue for the given time described above as this is usually when stents and catheters are removed.

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form. * stated availability for the duration of the study, and willingness to comply with all study procedures, including willingness to adhere to twice daily irrigation of neobladder or ileal conduit. * male or female, ≥ 18 years of age * confirmed diagnosis of bladder cancer * candidate for radical cystectomy with urinary diversion * ecog performance status of 0-2 * serum creatinine ≤ 1.5 mg/dl exclusion criteria: * has undergone or planned to undergo urinary diversion other than ileal conduit or neobladder. * pregnancy or lactation. * known allergic reactions to components of the irrisept irrigating system, chlorhexidine. * patient must not have any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.

Keywords: bladder cancer radical cystectomy ileal conduit neobladder chlorhexidine gluconate irrisept
chronic low back pain and neck pain prospective study

Conditions: Chronic Low Back Pain; Chronic Neck Pain

Summary: this prospective observation multifaceted study aims: 1. to perform a large prospective study and identify multiple "omics" biomarkers in chronic low back pain 2. to validate identified biomarkers for progression of acute to chronic low back pain 3. to validate identified biomarkers and test their heritability/validity in additional cohorts 4. to identify pathways and relevant individual variations for generation, propagation and subsidence of pain 5. to identify new imaging biomarkers related to chronic low back pain 6. to develop a registry of neck and low back pain subjects to help monitor the health-care management and utility to improve protocols and patient outcomes.

this novel study aims to identify genetic variants associated with chronic low back pain as well as "omics and imaging biomarkers". to achieve this, we will link and relate clinical data (clinical and neurological signs leading to anatomical diagnosis plus a careful evaluation of inflammatory response of patient) to a multiple "omics" analysis in order to investigate promising biomarkers that could answer unmet needs: identification of predisposition to develop chronic low back pain, diagnosis and an objective measure of pain intensity in order to correlate to its pathophysiology, and validate predictors of response to specific (drug) treatments.

Eligibility criteria:
inclusion criteria: * neck and/or low back pain * new cases\* * males and females * 18 years or older * willing to participate in the study short- and long-term exclusion criteria: * previous spine surgery * cognitively impaired * drug addiction * incarceration (prisoner) * history of infections, tumors, chronic inflammation (e.g. rheumatoid arthritis, ankylosing spondylitis) * congenital/syndromal * pregnant females * diagnosed psychological impairment * inability to read or write
effect of arthrospira platensis (spirulina) as an adjunct to scaling and root planing on salivary antioxidant levels in chronic periodontitis subjects

Conditions: Chronic Periodontitis

Summary: introduction- oxidative stress plays a causative role in pathogenesis of periodontal disease. it has been reported that spirulina platensis or its active ingredient c phycocyanin (cpc) exerts anti-inflammatory, anti-oxidative and inhibitory effects on prostaglandin and leukotriene biosynthesis. aim- to evaluate the effect of dietary spirulina as an adjunct to srp on salivary antioxidants level in cp subjects. materials and methods- the study was a randomized double-blind clinical and biochemical trial in which 70 subjects with cp in the age group of 40-55 years, reporting to department of periodontology, tkdc and rc, new pargaon, were equally and randomly divided into test group (tg) and control group (cg). tg was given 2 gm spirulina capsules daily, after meals for 1 month and cg was not given any supplementary diet. srp was done at baseline in tg and cg. whole saliva sample was collected. clinical and biochemical parameters will be recorded at baseline, 1 month \& 3 months.


Eligibility criteria:
inclusion criteria: 1. subjects with cp (moderate and severe)as per cdc criteria 2007. 2. patients without any known systemic diseases. exclusion criteria: 1. patients who have taken anti-inflammatory/antibiotic/antioxidant within 3 months of beginning of study. 2. subjects who have undergone periodontal treatment within six months of inception of study. 3. tobacco habits in any form and alcoholics. 4. pregnant and lactating women.
clinical application of ctc in operable breast cancer patients

Conditions: Breast Cancer

Summary: the investigators aim to evaluate the possibility of clinical application of ctc detection in samples or peripheral blood of breast cancer patients, so as to act as the new techniques or indicators of early diagnosis, therapy efficiency, or postoperative surveillance of breast cancer.


Eligibility criteria:
inclusion criteria: * written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures. * age of at least 18 and at most 70 years. * performance status (karnofsky-index) \>80%. * chemotherapy is necessary before or after surgery. * no clinical evidence of local recurrence or distant metastases. * complete staging work-up within 3 months prior to registration. all patients must have (bilateral) mammography or breast mri, chest x-ray; other tests may be performed as clinically indicated. * life expectancy of at least 2 years, disregarding the diagnosis of cancer. * adequate organ function including normal red and white blood count, platelets, serum creatinine, bilirubin, and transaminases within normal range of the institution. * patients must be available for and compliant to treatment and follow-up. * patients registered on this trial must be treated and followed up at the participating center. exclusion criteria: * known hypersensitivity reaction to the investigational compounds or incorporated substances. * local recurrence and/or metastasis of breast cancer. * no need of chemotherapy. * pregnant or lactating patients. patients of childbearing potential must have a negative pregnancy test (urine or serum) within 14 days prior to registration. * prior or concomitant secondary malignancy (except non-melanomatous skin cancer or carcinoma in situ of the uterine cervix). * any other serious medical pathology, such as congestive heart failure; unstable angina; history of myocardial infarction during the previous year; uncontrolled high risk arrhythmias. * other serious illness or medical condition that may interfere with the understanding and giving of informed consent and the conduct of the study. * concurrent treatment with other experimental drugs or any other anti-cancer therapy. * males.

Keywords: breast cancer ctc neoadjuvant chemotherapy adjuvant chemotherapy